Head-to-head · free

AbbVie vs Akanda Corp.

ABBV vs AKAN — return on capital, cash generation, margins and balance sheet side by side.

ABBV

2 / 3

measures where ABBV leads

AKAN

1 / 3

measures where AKAN leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureABBV · FY2025AKAN
Revenue$61.2B—
Net income$4.2B—
Revenue growth (yearly, multi-year)2.1%—
Free cash flow$17.8B—
Free cash flow margin29.1%—
Net cash / (debt)——
ROIC14.4%—
Return on equity——
Gross margin70.2%-60.5%
Operating margin32.8%-1931.0%
Net debt / EBITDA2.68x-2.93x

Figures are as reported by each company; latest fiscal year shown.

Where AbbVie's cash went (FY2025)

Capital spending
$1.2B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABBV profile →

Where Akanda Corp.'s cash went

Not reported yet.

Full AKAN profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons